BiotechTube

atorvastatin + atorvastatin

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

STEMI

Conditions

STEMI

Trial Timeline

Dec 1, 2009 → Jun 1, 2011

NCT ID
NCT01033058

About atorvastatin + atorvastatin

atorvastatin + atorvastatin is a approved stage product being developed by Pfizer for STEMI. The current trial status is unknown. This product is registered under clinical trial identifier NCT01033058. Target conditions include STEMI.

What happened to similar drugs?

11 of 20 similar drugs in STEMI were approved

Approved (11) Terminated (3) Active (7)
✅Baricitinib + CyclophosphamideEli LillyApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅EfalizumabMerckApproved
✅Evolocumab 140 MG/ML + Standard of care (SOC)AmgenApproved
✅AmbrisentanGilead SciencesApproved
✅BMS-986165Bristol Myers SquibbApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT01033058ApprovedUNKNOWN
NCT00739999Phase 1Completed
NCT00728988ApprovedCompleted
NCT00917579ApprovedCompleted
NCT00644670ApprovedCompleted

Competing Products

20 competing products in STEMI

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
47
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 2
35
E6742EisaiPhase 1/2
32
KHK4827Kyowa KirinPhase 1
29
KHK4827 + PlaceboKyowa KirinPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + CyclophosphamideEli LillyApproved
47
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32